A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Public ClinicalTrials.gov record NCT01376297. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Randomized, Double-blind, Unbalanced (3:1) Active Control Study to Assess the Safety and Describe the Efficacy of Netupitant and Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles.
Study identification
- NCT ID
- NCT01376297
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Enrollment
- 413 participants
Conditions and interventions
Conditions
Interventions
- Aprepitant Drug
- Dexamethasone Drug
- Netupitant and Palonosetron Drug
- Palonosetron Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2011
- Primary completion
- Aug 31, 2012
- Completion
- Not listed
- Last update posted
- Nov 16, 2014
Started 2011
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwest Alabama Cancer Center PC | Muscle Shoals | Alabama | 35661 | — |
| East Valley Hematology and Oncology Medical Group | Burbank | California | 91505 | — |
| American Institute of Research | Los Angeles | California | 90017 | — |
| Veterans Administration New Jersey Health Care System | East Orange | New Jersey | 07018 | — |
| Hematology Oncology Associates of Rockland | Nyack | New York | 10960 | — |
| Hematology and Oncology Associates, Inc. | Canton | Ohio | 44708 | — |
| Tri-County Hematology & Oncology Associates, Inc | Massillon | Ohio | 44646 | — |
| Cancer Center at Memorial Hospital of RI | Pawtucket | Rhode Island | 02860 | — |
| Spartanburg Regional Health Services | Spartanburg | South Carolina | 29303 | — |
| South Texas Comrehensive Cancer Centers | Corpus Christi | Texas | 78405 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01376297, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2014 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01376297 live on ClinicalTrials.gov.